Application of astilbin in aspect of preventing and treating Parkinson's disease

A technology for astilbin and Parkinson's disease, applied in the field of medical neuropharmacology, can solve the problems of large development space, insufficient exploration, unable to inhibit or delay the disease process, etc., and achieve the effect of improving neurons and improving the symptoms of motor retardation.

Inactive Publication Date: 2017-04-26
JIANGNAN UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, drug treatment is mostly symptomatic treatment, which can temporarily relieve symptoms, but cannot inhibit or delay the progress of the disease
The traditional Chinese medicine database is the essence and valuable resource of traditional medicine in my country. Although there have been researches on finding the potential for clinical treatment of Parkinson's disease in terms of monomer groups of traditional Chinese medicines, single Chinese medicines and their compound extraction parts, the exploration is still not enough. , there are still many potential monomers or monomer groups to be developed, and there is still a lot of room for development

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astilbin in aspect of preventing and treating Parkinson's disease
  • Application of astilbin in aspect of preventing and treating Parkinson's disease
  • Application of astilbin in aspect of preventing and treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Establishment and grouping of animal models

[0026] Body weight 20-25g, 8 weeks old, male C57BL / 6 mice, were randomly divided into control group, MPTP model group (first give MPTP and then give normal saline), astilbin administration group (first give MPTP and then give astilbin ), 20 per group. Placed at 23±2°C, the lighting time is 12h / day, and the animals are given drugs after one week of adaptation to the environment. The MPTP model group was intraperitoneally injected with MPTP (30 mg / kg) once a day for 5 consecutive days, and then injected with normal saline once a day for 7 consecutive days. The administration group was intraperitoneally injected with MPTP (30 mg / kg) once a day for 5 consecutive days, and then injected astilbin (50 mg / kg) solution once a day for 7 consecutive days. The control group was given normal saline for 12 consecutive days. Then the behavior of mice was evaluated by pole climbing test, and then the content of dopamine in str...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of astilbin in an aspect of preventing and treating Parkinson's disease, and belongs to the technical field of medical neuropharmacology. The invention relates to a potential application of a dihydroflavonol glycoside compound, namely the astilbin, in preparing a medicine for the clinical treatment of the Parkinson's disease. According to the application, by establishing an animal model of the Parkinson's disease and through the comprehensive utilization of various research methods including ethology, immunology, biochemical indexes and the like, experiments prove that the medicine can improve dyskinesia symptom in a model mouse of the Parkinson's disease and can relieve the degeneration of dopaminergic neuron of substantia nigra pars compacta; and the astilbin, which is rich in raw material source and good in effect, has a certain development value and a certain prospect in clinical application.

Description

technical field [0001] The invention relates to the application of astilbin in preventing and treating Parkinson's disease, and belongs to the technical field of medical neuropharmacology. Background technique [0002] Parkinson's disease (PD) is the most common degenerative disease of the motor nervous system, the main clinical manifestations are: resting tremor, slowness of movement, unsteady standing and postural reflex disorder. The main lesions in the brain of patients with Parkinson's disease are the substantia nigra and striatum. The death and reduction of dopaminergic neurons in the substantia nigra compacta is the direct cause of the decrease in dopamine projected to the striatum. As the second largest neurodegenerative disease after Alzheimer's disease, the incidence and prevalence of Parkinson's disease increase sharply with age, and the prevalence rate reaches 1% among the elderly over 60 years old. People over the age of 85 account for 5%-6%. At present, the num...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P25/16A23L33/105A23K10/30
CPCA23V2002/00A61K31/7048A23V2250/2116A23V2200/322
Inventor 申延琴朱营利徐一达
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap